Clinical aspects of three new progestogens: Desogestrel, gestodene, and norgestimate
- 1 May 1989
- journal article
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 160 (5) , 1296-1300
- https://doi.org/10.1016/s0002-9378(89)80016-x
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Effects of 180 μg and 250 μg norgestimate on pituitary-ovarian function and cervical mucusFertility and Sterility, 1988
- New progestogens in oral contraceptivesAmerican Journal of Obstetrics and Gynecology, 1987
- Gestoden, an innovative progestogenAdvances in Contraception, 1987
- Effects of norgestimate (0.250 mg) in combination with ethinyl estradiol (0.035 mg) on cervical mucusAdvances in Contraception, 1986
- The affinity of norgestimate for uterine progestogen receptors and its direct action on the uterusContraception, 1985
- Serum steroid binding protein concentrations, distribution of progestogens, and bioavailability of testosterone during treatment with contraceptives containing desogestrel or levonorgestrelFertility and Sterility, 1984
- Changes in serum apo-lipoprotein AI and sex-hormone-binding globul in levels after treatment with two different progestins administered alone and in combination with ethinyl estradiolContraception, 1984
- Biotransformation of norgestimate in womenContraception, 1984
- Two oral contraceptives, efficacy, serum proteins, and lipid metabolismContraception, 1982
- Optimum dosage of an oral contraceptiveAmerican Journal of Obstetrics and Gynecology, 1979